<DOC>
	<DOCNO>NCT00492284</DOCNO>
	<brief_summary>The objective study determine combination therapy ( reduced-fluence Visudyne follow Lucentis [ within 2 hour ] either two regimen reduced-fluence Visudyne follow Lucentis-Dexamethasone triple therapy [ within 2 hour ] ) reduce retreatment rate compare Lucentis monotherapy maintain similar vision outcome acceptable safety profile .</brief_summary>
	<brief_title>Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination AMD Lesions ( RADICAL )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Treatment naive choroidal neovascularization ( CNV ) secondary agerelated macular degeneration ( AMD ) study eye except laser treatment outside subfoveal area Subfoveal CNV due AMD CNV must = &gt; 50 % entire lesion All lesion composition type lesion great linear dimension ( GLD ) &lt; 5400 micron ( approximately = &lt; 9 disc area [ DA ] ) Bestcorrected Early Treatment Diabetic Retinopathy Study ( ETDRS ) visual acuity ( VA score ) 25 73 letter ( approximate Snellen equivalent 20/40 20/320 ) , inclusive Subfoveal geographic atrophy subfoveal fibrosis study eye Intraocular surgery within 3 month enrollment Inability attend protocolrequired visit Known allergy hypersensitivity study treatment . Other systemic disease active uncontrolled infection would make subject poor medical risk Uncontrolled glaucoma , define ( 1 ) subject &gt; 1 glaucoma medication ( include combination treatment ) ( 2 ) subject glaucoma could lead progressive visual field deterioration If subject stroke within last year</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Macular Degeneration</keyword>
	<keyword>AMD</keyword>
	<keyword>CNV</keyword>
	<keyword>Choroidal neovascularization</keyword>
	<keyword>Photodynamic therapy</keyword>
	<keyword>CNV Secondary Age Related Macular Degeneration</keyword>
</DOC>